GSK-Partnered Alector Hit By Renewed Dementia Skepticism

Doubts About Biomarker

 
• By Andrew McConaghie

Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker  neurofilament light chain.

Brain research
New investment is flooding into neuroscience, but understanding of disease mechanisms still lags far behind areas such as oncology and cardiovascular disease

More from Business

More from Scrip